ATE544774T1 - Rnai-modulation von mll-af4 und verwendungen dafür - Google Patents
Rnai-modulation von mll-af4 und verwendungen dafürInfo
- Publication number
- ATE544774T1 ATE544774T1 AT05854523T AT05854523T ATE544774T1 AT E544774 T1 ATE544774 T1 AT E544774T1 AT 05854523 T AT05854523 T AT 05854523T AT 05854523 T AT05854523 T AT 05854523T AT E544774 T1 ATE544774 T1 AT E544774T1
- Authority
- AT
- Austria
- Prior art keywords
- mll
- rnai modulation
- rnai
- modulation
- downregulation
- Prior art date
Links
- 108091030071 RNAI Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000003828 downregulation Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Inductance-Capacitance Distribution Constants And Capacitance-Resistance Oscillators (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Control Of El Displays (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63593604P | 2004-12-14 | 2004-12-14 | |
| US66839205P | 2005-04-05 | 2005-04-05 | |
| US69841405P | 2005-07-12 | 2005-07-12 | |
| PCT/US2005/045827 WO2006066158A2 (en) | 2004-12-14 | 2005-12-14 | Rnai modulation of mll-af4 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE544774T1 true ATE544774T1 (de) | 2012-02-15 |
Family
ID=36588628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05854523T ATE544774T1 (de) | 2004-12-14 | 2005-12-14 | Rnai-modulation von mll-af4 und verwendungen dafür |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US7361752B2 (https=) |
| EP (1) | EP1824872B1 (https=) |
| JP (2) | JP2008523157A (https=) |
| AT (1) | ATE544774T1 (https=) |
| AU (1) | AU2005316384B2 (https=) |
| CA (1) | CA2590768A1 (https=) |
| WO (1) | WO2006066158A2 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| WO2006066158A2 (en) * | 2004-12-14 | 2006-06-22 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of mll-af4 and uses thereof |
| JP5489459B2 (ja) * | 2005-08-01 | 2014-05-14 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 乳癌の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物 |
| CA2845251A1 (en) * | 2005-09-12 | 2007-03-22 | The Ohio State University Research Foundation | Compositions for the therapy of bcl2-associated cancers and methods of preparation thereof |
| US20090270484A1 (en) * | 2005-10-05 | 2009-10-29 | The Ohio State University Research Foundation | WWOX Vectors and Uses in Treatment of Cancer |
| US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
| EP2487258B1 (en) | 2006-01-05 | 2014-10-01 | The Ohio State University Research Foundation | MicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer |
| JP5490413B2 (ja) | 2006-01-05 | 2014-05-14 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常 |
| CN102943108B (zh) | 2006-01-05 | 2014-05-21 | 俄亥俄州立大学研究基金会 | 用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物 |
| ES2446362T3 (es) | 2006-03-20 | 2014-03-07 | The Ohio State University Research Foundation | Huellas de microARN durante megacariocipoyesis humana |
| US8367113B2 (en) | 2006-05-15 | 2013-02-05 | Massachusetts Institute Of Technology | Polymers for functional particles |
| WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| CA2657030A1 (en) | 2006-07-13 | 2008-01-17 | The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio | Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases |
| CN101535505A (zh) | 2006-09-19 | 2009-09-16 | 俄亥俄州立大学研究基金会 | 慢性淋巴细胞性白血病(CLL)中受miR-29和miR-181调控的TCL1的表达 |
| EP2087135B8 (en) | 2006-11-01 | 2013-07-24 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
| CN105256004A (zh) * | 2007-01-31 | 2016-01-20 | 俄亥俄州立大学研究基金会 | 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物 |
| US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
| EP2136788B1 (en) | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
| WO2008124632A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
| CA2685840C (en) * | 2007-04-30 | 2016-12-13 | The Ohio State University Research Foundation | Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis |
| ES2527648T3 (es) * | 2007-06-08 | 2015-01-28 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Métodos para determinar el subtipo de carcinoma hepatocelular |
| AR066984A1 (es) * | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| EP2719773A3 (en) | 2007-06-15 | 2014-07-30 | The Ohio State University Research Foundation | miRNA as marker for acute lamphomic leucemia |
| ES2496172T3 (es) * | 2007-07-31 | 2014-09-18 | The Ohio State University Research Foundation | Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B |
| JP2010535473A (ja) | 2007-08-03 | 2010-11-25 | ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン | ｎｃＲＮＡをコードする超保存領域 |
| CA2696887C (en) * | 2007-08-22 | 2016-06-28 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
| KR20100065190A (ko) | 2007-09-14 | 2010-06-15 | 닛토덴코 가부시키가이샤 | 약물 담체 |
| EP2630966B1 (en) | 2007-10-12 | 2017-04-19 | Massachusetts Institute of Technology | Vaccine nanotechnology |
| CN102137927B (zh) | 2007-10-26 | 2014-03-12 | 俄亥俄州立大学研究基金会 | 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途 |
| JP2011505143A (ja) * | 2007-11-30 | 2011-02-24 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | マイクロｒｎａ発現プロファイリング及び肺癌における末梢血ターゲティング |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| AU2009219193A1 (en) * | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | MicroRNA signatures associated with human chronic lymphocytic leukemia (CCL) and uses thereof |
| US20110054009A1 (en) * | 2008-02-28 | 2011-03-03 | The Ohio State University Research Foundation | MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Prostate Related Disorders |
| ES2433940T3 (es) | 2008-06-11 | 2013-12-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Uso de la familia miR-26 como marcador predictivo del carcinoma hepatocelular y sensibilidad a la terapia |
| WO2010023544A1 (en) * | 2008-08-28 | 2010-03-04 | Council Of Scientific & Industrial Research | Compositions and methods for delivery of protein-coding rnas to correct mitochondrial dysfunction |
| US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| CA2762653A1 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Immunomodulatory agent-polymeric compounds |
| ES2804764T3 (es) | 2009-06-01 | 2021-02-09 | Halo Bio Rnai Therapeutics Inc | Polinucleótidos para la interferencia de ARN multivalente, composiciones y métodos de uso de los mismos |
| EP3284494A1 (en) | 2009-07-30 | 2018-02-21 | Tandem Diabetes Care, Inc. | Portable infusion pump system |
| US8916533B2 (en) | 2009-11-23 | 2014-12-23 | The Ohio State University | Materials and methods useful for affecting tumor cell growth, migration and invasion |
| US8349308B2 (en) | 2010-03-26 | 2013-01-08 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| AU2011258165B2 (en) | 2010-05-26 | 2016-11-17 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| JP5931897B2 (ja) | 2010-11-12 | 2016-06-08 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法 |
| CA2817982C (en) | 2010-11-15 | 2020-06-30 | The Regents Of The University Of Michigan | Controlled release mucoadhesive systems |
| WO2012082894A1 (en) * | 2010-12-17 | 2012-06-21 | Arrowhead Research Corporation | Compositions and methods for inhibiting expression of mll genes |
| WO2012122239A1 (en) | 2011-03-07 | 2012-09-13 | The Ohio State University | MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER |
| JP2014521687A (ja) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア |
| AU2012323924A1 (en) | 2011-10-14 | 2014-05-29 | The Ohio State University | Methods and materials related to ovarian cancer |
| CA2859430A1 (en) | 2011-12-13 | 2013-06-20 | Ohio State Innovation Foundation | Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis |
| US8859202B2 (en) | 2012-01-20 | 2014-10-14 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
| JP2018525037A (ja) | 2015-08-24 | 2018-09-06 | ハロー−バイオ・アールエヌエーアイ・セラピューティックス、インコーポレイテッド | 遺伝子発現の調節のためのポリヌクレオチドナノ粒子及びその使用 |
| TN2019000308A1 (en) | 2017-07-06 | 2021-05-07 | Arrowhead Pharmaceuticals Inc | RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE |
| CN107964536B (zh) * | 2018-01-19 | 2021-10-22 | 上海交通大学医学院附属瑞金医院 | 一种实现人的诱导多能干细胞来源的造血干祖细胞强效体内移植的方法 |
| AU2022366987A1 (en) | 2021-10-14 | 2024-05-16 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
| KR20250068649A (ko) | 2022-09-13 | 2025-05-16 | 아스널 바이오사이언시스, 인크. | 공동 발현된 tgfbr shrna를 갖는 면역 세포 |
| EP4587570A2 (en) | 2022-09-16 | 2025-07-23 | Arsenal Biosciences, Inc. | Immune cells with combination gene perturbations |
| KR20250158048A (ko) | 2023-03-03 | 2025-11-05 | 아스널 바이오사이언시스, 인크. | Psma 및 ca9을 표적으로 하는 시스템 |
| WO2025199338A1 (en) | 2024-03-20 | 2025-09-25 | Arsenal Biosciences, Inc. | Systems targeting slc34a2 and tmprss4 and methods of use thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957735A (en) * | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5043164A (en) * | 1989-01-17 | 1991-08-27 | The University Of Tennessee Research Corporation | Blood-stable, cholesterol-free liposomes |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
| JP3351476B2 (ja) * | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
| US5853755A (en) * | 1993-07-28 | 1998-12-29 | Pharmaderm Laboratories Ltd. | Biphasic multilamellar lipid vesicles |
| US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5817856A (en) * | 1995-12-11 | 1998-10-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid and method |
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US7045292B2 (en) * | 1998-03-25 | 2006-05-16 | University Of Manitoba | Method and marker for identification of pre-malignancy and malignancy and therapeutic intervention |
| WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| EP1272630A2 (en) * | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| US20040259247A1 (en) * | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20030175950A1 (en) * | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| US7956176B2 (en) * | 2002-09-05 | 2011-06-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| EP2305812A3 (en) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| WO2004064737A2 (en) | 2003-01-17 | 2004-08-05 | Alnylam Pharmaceuticals | Therapeutics compositions |
| WO2004080406A2 (en) | 2003-03-07 | 2004-09-23 | Alnylam Pharmaceuticals | Therapeutic compositions |
| JP4991288B2 (ja) | 2003-04-17 | 2012-08-01 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 二本鎖ｉＲＮＡ剤、および二本鎖ｉＲＮＡ剤の対合の安定性を調節する方法。 |
| DK1620544T3 (en) | 2003-04-17 | 2019-01-14 | Alnylam Pharmaceuticals Inc | MODIFIED iRNA AGENTS |
| WO2006066158A2 (en) * | 2004-12-14 | 2006-06-22 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of mll-af4 and uses thereof |
| EP2719773A3 (en) * | 2007-06-15 | 2014-07-30 | The Ohio State University Research Foundation | miRNA as marker for acute lamphomic leucemia |
-
2005
- 2005-12-14 WO PCT/US2005/045827 patent/WO2006066158A2/en not_active Ceased
- 2005-12-14 EP EP05854523A patent/EP1824872B1/en not_active Expired - Lifetime
- 2005-12-14 JP JP2007546979A patent/JP2008523157A/ja active Pending
- 2005-12-14 US US11/303,367 patent/US7361752B2/en not_active Expired - Lifetime
- 2005-12-14 AT AT05854523T patent/ATE544774T1/de active
- 2005-12-14 CA CA002590768A patent/CA2590768A1/en not_active Abandoned
- 2005-12-14 AU AU2005316384A patent/AU2005316384B2/en not_active Expired
-
2008
- 2008-02-27 US US12/038,808 patent/US7674779B2/en not_active Expired - Lifetime
-
2010
- 2010-02-04 US US12/700,493 patent/US8034793B2/en not_active Expired - Lifetime
-
2011
- 2011-09-16 US US13/235,308 patent/US20120010267A1/en not_active Abandoned
- 2011-09-22 JP JP2011208167A patent/JP2011254840A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006066158A3 (en) | 2007-04-19 |
| EP1824872A2 (en) | 2007-08-29 |
| US20080233584A1 (en) | 2008-09-25 |
| US20060166918A1 (en) | 2006-07-27 |
| AU2005316384A1 (en) | 2006-06-22 |
| EP1824872B1 (en) | 2012-02-08 |
| WO2006066158A2 (en) | 2006-06-22 |
| US8034793B2 (en) | 2011-10-11 |
| CA2590768A1 (en) | 2006-06-22 |
| US20120010267A1 (en) | 2012-01-12 |
| US7674779B2 (en) | 2010-03-09 |
| EP1824872A4 (en) | 2008-11-26 |
| US7361752B2 (en) | 2008-04-22 |
| US20100256218A1 (en) | 2010-10-07 |
| AU2005316384B2 (en) | 2012-02-09 |
| JP2011254840A (ja) | 2011-12-22 |
| JP2008523157A (ja) | 2008-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE544774T1 (de) | Rnai-modulation von mll-af4 und verwendungen dafür | |
| WO2006036916A3 (en) | Rnai modulation of apob and uses thereof | |
| EA200901653A1 (ru) | ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC | |
| EA200800868A1 (ru) | Модуляция экспрессии глюкокортикоидного рецептора | |
| EP1629084A4 (en) | MODULATION OF C-REACTIVE PROTEIN EXPRESSION | |
| IL235342B (en) | Use of hsp70 as a regulator of enzymatic activity | |
| EA201492119A1 (ru) | Композиции и способы для модулирования экспрессии apoa1 и abca1 | |
| NO20081884L (no) | Modulasjon av glukagonreseptorekspresjon | |
| EA201492117A1 (ru) | Композиции и способы для модулирования экспрессии bdnf | |
| MX2010003606A (es) | Modulacion antisentido de la expresion del receptor del factor de crecimiento fibroblastico 4. | |
| DE60143901D1 (de) | Antisense-modulation der clusterinexpression | |
| EA200971077A1 (ru) | Гетероциклические модуляторы киназы | |
| JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
| DE602005022319D1 (de) | Modifizierte pyrimidin-glucocorticoid-rezeptor-modulatoren | |
| ECSP067014A (es) | Modulación de producción de inmunoglobulina y trastornos atópicos | |
| EA200802111A1 (ru) | Имплантаты для лечения состояний, ассоциируемых с допамином | |
| DE602005017753D1 (de) | Mittel für die transdermale verabreichung von nikotin | |
| WO2007014077A3 (en) | Rnai modulation of the rho-a gene and uses thereof | |
| CL2004000064A1 (es) | Compuestos derivados de alquilamido piperdinas, composicion farmaceutica, utiles para tratar depresion, desorden bipolar, fobia social, incontinencia urinaria, obesidad, bulimia, anorexia nerviosa y otros. | |
| EA200970472A1 (ru) | Замещенные пиразолы, композиции, их содержащие, способ получения и применение | |
| ATE539758T1 (de) | Rnai-modulation des bcr-abl-fusionsgens und dessen verwendungen | |
| WO2009071680A3 (en) | Rna antagonist compounds for the modulation of mcl-1 | |
| CY1116319T1 (el) | Συνθεσεις που περιλαμβανουν core-1 θετικο μικροοργανισμο και χρηση αυτων για την αντιμετωπιση ή προφυλαξη απο ογκους | |
| WO2006081192A3 (en) | Rnai modulation of the nogo-l or nogo-r gene and uses thereof | |
| AU2018256632A1 (en) | RNAi inhibition of alpha-ENaC expression |